Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies: A National Registry Dataset Analysis

Nicolò Matteo Luca Battisti, Catherine A. Welch, Michael Sweeting, Mark de Belder, John Deanfield, Clive Weston, Michael D. Peake, David Adlam*, Alistair Ring

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background: Although a common challenge for patients and clinicians, there is little population-level evidence on the prevalence of cardiovascular disease (CVD) in individuals diagnosed with potentially curable cancer. Objectives: We investigated CVD rates in patients with common potentially curable malignancies and evaluated the associations between patient and disease characteristics and CVD prevalence. Methods: The study included cancer registry patients diagnosed in England with stage I to III breast cancer, stage I to III colon or rectal cancer, stage I to III prostate cancer, stage I to IIIA non-small-cell lung cancer, stage I to IV diffuse large B-cell lymphoma, and stage I to IV Hodgkin lymphoma from 2013 to 2018. Linked hospital records and national CVD databases were used to identify CVD. The rates of CVD were investigated according to tumor type, and associations between patient and disease characteristics and CVD prevalence were determined. Results: Among the 634,240 patients included, 102,834 (16.2%) had prior CVD. Men, older patients, and those living in deprived areas had higher CVD rates. Prevalence was highest for non-small-cell lung cancer (36.1%) and lowest for breast cancer (7.7%). After adjustment for age, sex, the income domain of the Index of Multiple Deprivation, and Charlson comorbidity index, CVD remained higher in other tumor types compared to breast cancer patients. Conclusions: There is a significant overlap between cancer and CVD burden. It is essential to consider CVD when evaluating national and international treatment patterns and cancer outcomes.

Original languageEnglish
Pages (from-to)238-253
Number of pages16
JournalJACC: CardioOncology
Issue number2
Publication statusPublished - Jun 2022

Bibliographical note

Funding Information:
This study was funded by a joint research grant from the British Heart Foundation (SP/16/5/32415) and Cancer Research UK (C53325/A21134). The funders did not have any involvement in producing the report. Dr Battisti has received advisory board fees from Pfizer, Abbott and Sanofi; has received travel grants from Exact Sciences, Eli Lilly and Pfizer; and has received speaker fees from Pfizer and Abbvie. Dr Ring has received advisory board and speaker fees from Roche, Novartis, Pfizer, Merck Sharpe & Dohme, AstraZeneca, Seagen, Daiichi Sankyo, and Eli Lilly. Dr Adlam has received research funding and in-kind support from AstraZeneca for unrelated research; has received educational funding from Abbott Vascular to support a clinical research fellow; and has conducted consultancy for General Electric to support general research funds. Mr Sweeting is a full-time employee of AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Funding Information:
This project involves data that has been provided by, or derived from patients and collected by the NHS as part of their care and support. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE) and data has also been provided by the Healthcare Quality Improvement Partnership from the National Cardiac Audit Programme, part of the National Clinical Audit and Patient Outcomes Programme which they commission. Access to the data was facilitated by the PHE Office for Data Release.

Publisher Copyright:
© 2022 The Authors


  • breast cancer
  • colorectal cancer
  • lung cancer
  • lymphoma
  • prostate cancer


Dive into the research topics of 'Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies: A National Registry Dataset Analysis'. Together they form a unique fingerprint.

Cite this